Biotech News

Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Annexon, Inc. (ANNX)Annexon, Inc.Earnings

Differentiated C1q Platform Advances Two Registrational Programs with Blockbuster Potential, Driving Near-Term Value Catalysts Tanruprubart U.S./EU FORWARD Data in GBS Strengthens BLA Submission Package Anticipated in Q4 2026; Tanruprubart EU MAA Currently Under Review Vonaprument ARCHER II Phase

Related news

Annexon, Inc.

Classical Complement Inhibition Annexon develops therapies that inhibit the classical complement pathway, which can drive harmful inflammation and tissue damage in neurologic, ophthalmic, and autoimmune diseases. Tanruprubart Tanruprubart is an antibody therapy for Guillain-Barré syndrome. Its European marketing application is under...

Recent company news

Stock data

Close
3.41 USD
Market cap
861.81M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States